title: Transplantation for amyloidosis.
abstract: OBJECTIVE
  High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature.
  
  
  RESULTS
  We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial.
  
  
  CONCLUSIONS
  Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.
authors.affiliation: Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. gertz.morie@mayo.edu
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
authors.forename: Martha Q
authors.initials: MQ
authors.lastname: Lacy
authors.forename: Angela
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: Suzanne R
authors.initials: SR
authors.lastname: Hayman
authors.forename: Shaji
authors.initials: S
authors.lastname: Kumar
mesh_terms: D000686:Amyloidosis / Q000145:classification / Q000401:mortality / Q000628:therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy; D011379:Prognosis; D033581:Stem Cell Transplantation; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents